SCHEMBL3959613

SCHEMBL3959613

COc1cccc(-c2cn(C3CCN(C(=O)OC(C)(C)C)CC3)c(=O)[nH]2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
EGFR P00533 1/20 0.53
SRC P12931 1/20 0.53
ABL2 P42684 1/20 0.53
CALCRL Q16602 3/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 1/20 0.46
CTSD P07339 1/20 0.45
CTSE P14091 1/20 0.45
BACE1 P56817 1/20 0.45
HCAR1 Q9BXC0 1/20 0.44
STS P08842 1/20 0.44
TGFBR1 P36897 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968550 0.89 EGFR (0.51) ABL1EGFRSRCABL2CALCRL
SCHEMBL3962648 0.88 STS (0.48) ABL1EGFRSRCABL2CALCRL
SCHEMBL3964847 0.88 HCAR1 (0.44) ABL1EGFRSRCABL2CALCRL
SCHEMBL3963952 0.88 ALDH1A1 (0.54) SRCCALCRLMEN1KMT2AALDH1A1
SCHEMBL2104155 0.88 DRD2 (0.56) EGFRSRCCALCRLKDM4EHCAR1
SCHEMBL3960277 0.87 CALCRL (0.43) CALCRLKDM4EHCAR1STSTGFBR1
SCHEMBL3956545 0.86 PRKCG (0.46) CALCRLALDH1A1KDM4EHPGDNPSR1
SCHEMBL3964155 0.86 DRD2 (0.54) EGFRSRCCALCRLHCAR1PRKCG
SCHEMBL3962602 0.85 MAPT (0.44) ABL1EGFRSRCABL2CALCRL
SCHEMBL5374613 0.83 CALCRL (0.41) CALCRLHCAR1STSTGFBR1PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US disclosed
EP-1440976-B1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production BOEHRINGER INGELHEIM PHARMA (DE) 2008-07-23 EP disclosed
WO-2008070014-A2 BIARYL KETONE-SUBSTITUTED PIPERIDINES NEUROGEN CORPORATION (US) 2008-06-12 WO disclosed
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2004-10-28 US disclosed
EP-1440976-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-28 EP disclosed
EP-0927192-B1 MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION BOEHRINGER INGELHEIM PHARMA (DE) 2004-05-12 EP disclosed
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2003-04-10 US disclosed
US-6344449-B1 HEADACHE AND MORPHINE DEPENDENCE DR. KARL THOMAE GMBH (DE) 2002-02-05 US disclosed
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2001-11-01 US disclosed
EP-0927192-A1 MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION Dr. Karl Thomae GmbH (DE) 1999-07-07 EP disclosed
WO-1998011128-A1 MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION DR. KARL THOMAE GMBH (DE) 1998-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS ABL1 689/4885EGFR 1121/4885SRC 2618/4885
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 ABL1 802/4885EGFR 1136/4885SRC 2807/4885
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production SLC1A5, NEFM, SRMS ABL1 1002/4885EGFR 1360/4885SRC 3573/4885
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 ABL1 802/4885EGFR 1136/4885SRC 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.